TSN
40
-2
GT
65
3
USB
57
2
WAT
57
2
TDC
83
3
NAVI
55
3
INTC
43
10
NSC
65
5
MMC
65
3
XEL
71
2
CPB
35
5
EL
31
6
FOXA
52
-7
ORCL
63
-2
CRM
65
-2
KR
44
6
LRCX
48
5
FCX
61
3
CI
55
3
BAX
32
2
TSN
40
-2
GT
65
3
USB
57
2
WAT
57
2
TDC
83
3
NAVI
55
3
INTC
43
10
NSC
65
5
MMC
65
3
XEL
71
2
CPB
35
5
EL
31
6
FOXA
52
-7
ORCL
63
-2
CRM
65
-2
KR
44
6
LRCX
48
5
FCX
61
3
CI
55
3
BAX
32
2
Financhill
Back

The Vita Coco 10K Form

Buy
59

COCO
The Vita Coco

Last Price:
35.91
Seasonality Move:
-3.68%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive COCO News And Ratings

See the #1 stock for the next 7 days that we like better than COCO

COCO Financial Statistics

Sales & Book Value

Annual Sales: $493.61M
Cash Flow: $8.89M
Price / Cash Flow: 29.79
Annual Sales: $4.44
Price / Book: 8.18

Profitability

EPS (TTM): 0.99000
Net Income (TTM): $59.36M
Gross Margin: $180.73M
Return on Equity: 27.26%
Return on Assets: 19.53%

The Vita Coco Earnings Forecast

Key The Vita Coco Financial Ratios

  • The Gross Profit Margin over the past 15 years for COCO is 36.61%.
  • The Selling, General & Administrative Expenses for COCO have been equal to 25.17% of Gross Profit Margin.
  • The Research & Development expenses have been 0.00% of Revenue.
  • The Interest Expense is 0.07% of Operating Income.
  • The Net Earning history of COCO is 9.45% of Total Revenues.
  • Per Share Earnings over the last 15 years have been positive in 8 years.

The Vita Coco Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Beverages
Sector: Consumer Staples
Current Symbol: COCO
CUSIP: 218868
Website: thevitacococompany.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 3.28
Quick Ratio: 2.34

Price-to-Earnings

Trailing P/E Ratio: 46
Forward P/E Ratio: 31.42

COCO Technical Analysis vs Fundamental Analysis

Buy
59
The Vita Coco (COCO) is a Buy

Is The Vita Coco a Buy or a Sell?

  • The Vita Coco stock is rated a Buy
    The current The Vita Coco [COCO] share price is $36.34. The Score for COCO is 59, which is 18% above its historic median score of 50, and infers lower risk than normal.